Vycor Medical reported financial results for 2024, highlighting steady growth and strategic developments in its medical technology business. The company's Vycor Medical division saw revenues increase by 10% compared to 2023, with US hospital sales rising 17% and 11 new hospitals added to its customer base.
The company's flagship product, the ViewSite Brain Access System (VBAS), continued to gain clinical validation through eight new peer-reviewed studies. A significant 106-patient study evaluated the system's effectiveness in glioma removal, demonstrating its potential to improve surgical outcomes by reducing tissue damage and enhancing visualization during brain procedures.
Financially, Vycor Medical generated total revenue of $1,589,324 for the year, representing a 9% increase from 2023. The company maintained strong gross margins around 90% and invested in product development and regulatory compliance, including transitioning to Medical Device Regulation (MDR) standards in the European Union.
The organization also engaged Maxim Group LLC to explore strategic growth opportunities, including potential acquisitions, partnerships, and the possibility of uplisting to a major US stock exchange. These efforts aim to position the company for future expansion and increased stakeholder value.
Despite global trade uncertainties and potential tariff impacts, Vycor Medical's US-based manufacturing and diverse export markets provide some insulation from international economic fluctuations. The company remains focused on advancing its minimally invasive surgical technologies and vision rehabilitation therapies.
